[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fdWI4axvjH30Bv6NmoqD0paOsB4UNy7UleAeYLioQKJs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":58,"rows":65},"Technical University of Munich",[4],312,false,48,13,429698,6,252,[14,16,18,20,23,25,27,29],{"name":15,"count":11},"Breast Cancer",{"name":17,"count":11},"Schizophrenia",{"name":19,"count":11},"Obesity",{"name":21,"count":22},"Colon Adenoma",5,{"name":24,"count":22},"Anesthesia",{"name":26,"count":22},"Critical Care",{"name":28,"count":22},"Critical Illness",{"name":30,"count":31},"Diabetes Mellitus, Type 1",4,[33,38,43,48,53],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06179719","EEG-fMRI Experiments During Anesthesia Induction With Propofol","2024-09-10","Propofol",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT04600362","Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema","2025-09-01","Experimental: Dupilumab 300 MG\u002F2 ML Subcutaneous Solution [DUPIXENT]",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT05983588","PROFIL Study to Investigate the Effect of GPB on NfL Levels in Patients With Corticobasal Syndrome (CBS)","2026-03-30","RAVICTI 1.1 g\u002Fml",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05931575","Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease","2026-09-30","Fasudil hydrochloride",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT06452654","Anti-viral Action Against Type 1 Diabetes Autoimmunity","2027-10","Comirnaty Injectable Product",[59,60,61,62,63,64],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[66,90,108,129,151,173,228,285,314,338,367,385,403,421,439,457,475,493,511,529,547,565,583,601,619,637,655,673,691,709,735,762,780,806,830,848,866,892,922,940,958,976,994,1012,1041,1059,1077,1095,1121,1139,1157,1181,1199,1253,1308,1350,1381,1407,1441,1459,1477,1495,1513,1531,1549,1567,1585,1603,1621,1649,1667,1694,1717,1735,1758,1776,1794,1820,1845,1868,1893,1916,1934,1952,1970,1988,2014,2038,2064,2090,2114,2132,2158,2176,2194,2219,2237,2255,2289,2307,2325,2343,2361,2392,2426,2444,2462,2480,2505,2528,2554,2572,2590,2615],{"intervention":57,"totalTrials":67,"cells":68},1,{"EARLY_PHASE1":69,"PHASE1":72,"PHASE2":74,"PHASE3":76,"PHASE4":78,"NA":88},{"trials":70,"activeCount":71},[],0,{"trials":73,"activeCount":71},[],{"trials":75,"activeCount":71},[],{"trials":77,"activeCount":71},[],{"trials":79,"activeCount":67,"soonestReadout":56},[80],{"nctId":54,"briefTitle":55,"status":81,"phases":82,"primaryCompletion":56,"completion":56,"start":83,"enrollment":84,"conditions":85,"interventions":86},"RECRUITING",[63],"2024-05-08",2252,[30],[57,87],"Sodium Chloride 0.9% Inj",{"trials":89,"activeCount":71},[],{"intervention":87,"totalTrials":67,"cells":91},{"EARLY_PHASE1":92,"PHASE1":94,"PHASE2":96,"PHASE3":98,"PHASE4":100,"NA":106},{"trials":93,"activeCount":71},[],{"trials":95,"activeCount":71},[],{"trials":97,"activeCount":71},[],{"trials":99,"activeCount":71},[],{"trials":101,"activeCount":67,"soonestReadout":56},[102],{"nctId":54,"briefTitle":55,"status":81,"phases":103,"primaryCompletion":56,"completion":56,"start":83,"enrollment":84,"conditions":104,"interventions":105},[63],[30],[57,87],{"trials":107,"activeCount":71},[],{"intervention":52,"totalTrials":67,"cells":109},{"EARLY_PHASE1":110,"PHASE1":112,"PHASE2":114,"PHASE3":123,"PHASE4":125,"NA":127},{"trials":111,"activeCount":71},[],{"trials":113,"activeCount":71},[],{"trials":115,"activeCount":67,"soonestReadout":51},[116],{"nctId":49,"briefTitle":50,"status":81,"phases":117,"primaryCompletion":51,"completion":51,"start":118,"enrollment":119,"conditions":120,"interventions":122},[61],"2023-09-11",75,[121],"Idiopathic Parkinson´s Disease",[52],{"trials":124,"activeCount":71},[],{"trials":126,"activeCount":71},[],{"trials":128,"activeCount":71},[],{"intervention":47,"totalTrials":67,"cells":130},{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":145,"PHASE4":147,"NA":149},{"trials":132,"activeCount":71},[],{"trials":134,"activeCount":71},[],{"trials":136,"activeCount":67,"soonestReadout":46},[137],{"nctId":44,"briefTitle":45,"status":138,"phases":139,"primaryCompletion":46,"completion":46,"start":140,"enrollment":141,"conditions":142,"interventions":144},"ACTIVE_NOT_RECRUITING",[61],"2023-12-12",32,[143],"Corticobasal Syndrome (CBS)",[47],{"trials":146,"activeCount":71},[],{"trials":148,"activeCount":71},[],{"trials":150,"activeCount":71},[],{"intervention":42,"totalTrials":67,"cells":152},{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":167,"PHASE4":169,"NA":171},{"trials":154,"activeCount":71},[],{"trials":156,"activeCount":71},[],{"trials":158,"activeCount":67,"soonestReadout":41},[159],{"nctId":39,"briefTitle":40,"status":138,"phases":160,"primaryCompletion":41,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":166},[61],"2027-01-31","2021-03-30",70,[165],"Nummular Eczema",[42],{"trials":168,"activeCount":71},[],{"trials":170,"activeCount":71},[],{"trials":172,"activeCount":71},[],{"intervention":37,"totalTrials":31,"cells":174},{"EARLY_PHASE1":175,"PHASE1":177,"PHASE2":179,"PHASE3":181,"PHASE4":183,"NA":209},{"trials":176,"activeCount":71},[],{"trials":178,"activeCount":71},[],{"trials":180,"activeCount":71},[],{"trials":182,"activeCount":71},[],{"trials":184,"activeCount":71},[185,199],{"nctId":186,"briefTitle":187,"status":188,"phases":189,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":195},"NCT00534586","Anesthetics and Auditory, Visceral, and Heat Evoked Potentials","COMPLETED",[63],"2007-05","2005-12",60,[194],"Healthy",[37,196,197,198],"Remifentanil","S-Ketamine","Sevoflurane",{"nctId":200,"briefTitle":201,"status":202,"phases":203,"completion":204,"start":204,"enrollment":205,"conditions":206,"interventions":207},"NCT00408941","EEG and Auditory Evoked Potentials During Local Anesthesia","UNKNOWN",[63],"2006-12",15,[194],[37,208],"Prilocaine",{"trials":210,"activeCount":67,"soonestReadout":36},[211,218],{"nctId":34,"briefTitle":35,"status":81,"phases":212,"primaryCompletion":36,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":217},[64],"2026-09-10","2023-09-10",35,[24],[37],{"nctId":219,"briefTitle":220,"status":188,"phases":221,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":227},"NCT00290108","The Influence of Injection Rate on EEG Propofol Peak Effect as Measured by Bispectral Index",[64],"2003-12","2003-03",99,[226,194],"Elective Surgery",[37],{"intervention":229,"totalTrials":230,"cells":231},"Quetiapine",2,{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":238,"PHASE4":252,"NA":283},{"trials":233,"activeCount":71},[],{"trials":235,"activeCount":71},[],{"trials":237,"activeCount":71},[],{"trials":239,"activeCount":71},[240],{"nctId":241,"briefTitle":242,"status":188,"phases":243,"primaryCompletion":244,"start":245,"enrollment":246,"conditions":247,"interventions":249},"NCT00782405","Effect of Quetiapine XR on Sleep in Patients With Major Depression, as Compared With Mirtazapine",[62],"2011-04","2008-10",40,[248],"Sleep",[250,251],"quetiapine","mirtazapine",{"trials":253,"activeCount":71},[254],{"nctId":255,"briefTitle":256,"status":188,"phases":257,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":261,"interventions":264},"NCT02307396","Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients",[63],"2016-06-22","2015-02-01",21,[17,262,263],"Schizophrenia and Disorders With Psychotic Features","Schizoaffective Disorders",[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],"Olanzapine","Amisulpride","Risperidone","Haloperidol","Perphenazine","Sulpiride","bromperidol","Zuclopenthixol","Thioridazine","Paliperidone","Ziprasidone","Benperidol","Fluspirilene","Pimozide","Perazine","Fluphenazine","Flupentixole","Sertindole",{"trials":284,"activeCount":71},[],{"intervention":198,"totalTrials":230,"cells":286},{"EARLY_PHASE1":287,"PHASE1":300,"PHASE2":302,"PHASE3":304,"PHASE4":306,"NA":312},{"trials":288,"activeCount":71},[289],{"nctId":290,"briefTitle":291,"status":188,"phases":292,"primaryCompletion":293,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":299},"NCT02149927","Neural Mechanisms of Sevoflurane Induced Anesthesia: an EEG fMRI Study in Healthy Volunteers",[59],"2013-12","2014-01","2013-06",20,[24,298],"Drug Effects",[198],{"trials":301,"activeCount":71},[],{"trials":303,"activeCount":71},[],{"trials":305,"activeCount":71},[],{"trials":307,"activeCount":71},[308],{"nctId":186,"briefTitle":187,"status":188,"phases":309,"completion":190,"start":191,"enrollment":192,"conditions":310,"interventions":311},[63],[194],[37,196,197,198],{"trials":313,"activeCount":71},[],{"intervention":315,"totalTrials":67,"cells":316},"Sugammadex, Neostigmine, Saline",{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":323,"PHASE4":325,"NA":336},{"trials":318,"activeCount":71},[],{"trials":320,"activeCount":71},[],{"trials":322,"activeCount":71},[],{"trials":324,"activeCount":71},[],{"trials":326,"activeCount":71},[327],{"nctId":328,"briefTitle":329,"status":188,"phases":330,"primaryCompletion":331,"completion":331,"start":332,"enrollment":224,"conditions":333,"interventions":335},"NCT00895609","Sugammadex and Neostigmine at Shallow Neuromuscular Blockade",[63],"2009-08","2009-03",[334],"Neuromuscular Block",[315],{"trials":337,"activeCount":71},[],{"intervention":339,"totalTrials":67,"cells":340},"Acetylcysteine",{"EARLY_PHASE1":341,"PHASE1":343,"PHASE2":345,"PHASE3":347,"PHASE4":349,"NA":365},{"trials":342,"activeCount":71},[],{"trials":344,"activeCount":71},[],{"trials":346,"activeCount":71},[],{"trials":348,"activeCount":71},[],{"trials":350,"activeCount":71},[351],{"nctId":352,"briefTitle":353,"status":188,"phases":354,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":363},"NCT00492518","Acetylcysteine, Theophylline, and a Combination of Both in the Prophylaxis of Contrast-Induced Nephropathy",[63],"2004-10","2002-02",254,[359,360,361,362],"Contrast Induced Nephropathy","Kidney Diseases","Renal Failure","Adverse Effects",[339,364],"Theophylline",{"trials":366,"activeCount":71},[],{"intervention":364,"totalTrials":67,"cells":368},{"EARLY_PHASE1":369,"PHASE1":371,"PHASE2":373,"PHASE3":375,"PHASE4":377,"NA":383},{"trials":370,"activeCount":71},[],{"trials":372,"activeCount":71},[],{"trials":374,"activeCount":71},[],{"trials":376,"activeCount":71},[],{"trials":378,"activeCount":71},[379],{"nctId":352,"briefTitle":353,"status":188,"phases":380,"completion":355,"start":356,"enrollment":357,"conditions":381,"interventions":382},[63],[359,360,361,362],[339,364],{"trials":384,"activeCount":71},[],{"intervention":265,"totalTrials":67,"cells":386},{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":393,"PHASE4":395,"NA":401},{"trials":388,"activeCount":71},[],{"trials":390,"activeCount":71},[],{"trials":392,"activeCount":71},[],{"trials":394,"activeCount":71},[],{"trials":396,"activeCount":71},[397],{"nctId":255,"briefTitle":256,"status":188,"phases":398,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":399,"interventions":400},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":402,"activeCount":71},[],{"intervention":266,"totalTrials":67,"cells":404},{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":411,"PHASE4":413,"NA":419},{"trials":406,"activeCount":71},[],{"trials":408,"activeCount":71},[],{"trials":410,"activeCount":71},[],{"trials":412,"activeCount":71},[],{"trials":414,"activeCount":71},[415],{"nctId":255,"briefTitle":256,"status":188,"phases":416,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":417,"interventions":418},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":420,"activeCount":71},[],{"intervention":267,"totalTrials":67,"cells":422},{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":427,"PHASE3":429,"PHASE4":431,"NA":437},{"trials":424,"activeCount":71},[],{"trials":426,"activeCount":71},[],{"trials":428,"activeCount":71},[],{"trials":430,"activeCount":71},[],{"trials":432,"activeCount":71},[433],{"nctId":255,"briefTitle":256,"status":188,"phases":434,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":435,"interventions":436},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":438,"activeCount":71},[],{"intervention":268,"totalTrials":67,"cells":440},{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":447,"PHASE4":449,"NA":455},{"trials":442,"activeCount":71},[],{"trials":444,"activeCount":71},[],{"trials":446,"activeCount":71},[],{"trials":448,"activeCount":71},[],{"trials":450,"activeCount":71},[451],{"nctId":255,"briefTitle":256,"status":188,"phases":452,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":453,"interventions":454},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":456,"activeCount":71},[],{"intervention":269,"totalTrials":67,"cells":458},{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":465,"PHASE4":467,"NA":473},{"trials":460,"activeCount":71},[],{"trials":462,"activeCount":71},[],{"trials":464,"activeCount":71},[],{"trials":466,"activeCount":71},[],{"trials":468,"activeCount":71},[469],{"nctId":255,"briefTitle":256,"status":188,"phases":470,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":471,"interventions":472},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":474,"activeCount":71},[],{"intervention":270,"totalTrials":67,"cells":476},{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":485,"NA":491},{"trials":478,"activeCount":71},[],{"trials":480,"activeCount":71},[],{"trials":482,"activeCount":71},[],{"trials":484,"activeCount":71},[],{"trials":486,"activeCount":71},[487],{"nctId":255,"briefTitle":256,"status":188,"phases":488,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":489,"interventions":490},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":492,"activeCount":71},[],{"intervention":271,"totalTrials":67,"cells":494},{"EARLY_PHASE1":495,"PHASE1":497,"PHASE2":499,"PHASE3":501,"PHASE4":503,"NA":509},{"trials":496,"activeCount":71},[],{"trials":498,"activeCount":71},[],{"trials":500,"activeCount":71},[],{"trials":502,"activeCount":71},[],{"trials":504,"activeCount":71},[505],{"nctId":255,"briefTitle":256,"status":188,"phases":506,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":507,"interventions":508},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":510,"activeCount":71},[],{"intervention":272,"totalTrials":67,"cells":512},{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":519,"PHASE4":521,"NA":527},{"trials":514,"activeCount":71},[],{"trials":516,"activeCount":71},[],{"trials":518,"activeCount":71},[],{"trials":520,"activeCount":71},[],{"trials":522,"activeCount":71},[523],{"nctId":255,"briefTitle":256,"status":188,"phases":524,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":525,"interventions":526},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":528,"activeCount":71},[],{"intervention":273,"totalTrials":67,"cells":530},{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":545},{"trials":532,"activeCount":71},[],{"trials":534,"activeCount":71},[],{"trials":536,"activeCount":71},[],{"trials":538,"activeCount":71},[],{"trials":540,"activeCount":71},[541],{"nctId":255,"briefTitle":256,"status":188,"phases":542,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":543,"interventions":544},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":546,"activeCount":71},[],{"intervention":274,"totalTrials":67,"cells":548},{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":557,"NA":563},{"trials":550,"activeCount":71},[],{"trials":552,"activeCount":71},[],{"trials":554,"activeCount":71},[],{"trials":556,"activeCount":71},[],{"trials":558,"activeCount":71},[559],{"nctId":255,"briefTitle":256,"status":188,"phases":560,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":561,"interventions":562},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":564,"activeCount":71},[],{"intervention":275,"totalTrials":67,"cells":566},{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":573,"PHASE4":575,"NA":581},{"trials":568,"activeCount":71},[],{"trials":570,"activeCount":71},[],{"trials":572,"activeCount":71},[],{"trials":574,"activeCount":71},[],{"trials":576,"activeCount":71},[577],{"nctId":255,"briefTitle":256,"status":188,"phases":578,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":579,"interventions":580},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":582,"activeCount":71},[],{"intervention":276,"totalTrials":67,"cells":584},{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":591,"PHASE4":593,"NA":599},{"trials":586,"activeCount":71},[],{"trials":588,"activeCount":71},[],{"trials":590,"activeCount":71},[],{"trials":592,"activeCount":71},[],{"trials":594,"activeCount":71},[595],{"nctId":255,"briefTitle":256,"status":188,"phases":596,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":597,"interventions":598},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":600,"activeCount":71},[],{"intervention":277,"totalTrials":67,"cells":602},{"EARLY_PHASE1":603,"PHASE1":605,"PHASE2":607,"PHASE3":609,"PHASE4":611,"NA":617},{"trials":604,"activeCount":71},[],{"trials":606,"activeCount":71},[],{"trials":608,"activeCount":71},[],{"trials":610,"activeCount":71},[],{"trials":612,"activeCount":71},[613],{"nctId":255,"briefTitle":256,"status":188,"phases":614,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":615,"interventions":616},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":618,"activeCount":71},[],{"intervention":278,"totalTrials":67,"cells":620},{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":627,"PHASE4":629,"NA":635},{"trials":622,"activeCount":71},[],{"trials":624,"activeCount":71},[],{"trials":626,"activeCount":71},[],{"trials":628,"activeCount":71},[],{"trials":630,"activeCount":71},[631],{"nctId":255,"briefTitle":256,"status":188,"phases":632,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":633,"interventions":634},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":636,"activeCount":71},[],{"intervention":279,"totalTrials":67,"cells":638},{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":645,"PHASE4":647,"NA":653},{"trials":640,"activeCount":71},[],{"trials":642,"activeCount":71},[],{"trials":644,"activeCount":71},[],{"trials":646,"activeCount":71},[],{"trials":648,"activeCount":71},[649],{"nctId":255,"briefTitle":256,"status":188,"phases":650,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":651,"interventions":652},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":654,"activeCount":71},[],{"intervention":280,"totalTrials":67,"cells":656},{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":661,"PHASE3":663,"PHASE4":665,"NA":671},{"trials":658,"activeCount":71},[],{"trials":660,"activeCount":71},[],{"trials":662,"activeCount":71},[],{"trials":664,"activeCount":71},[],{"trials":666,"activeCount":71},[667],{"nctId":255,"briefTitle":256,"status":188,"phases":668,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":669,"interventions":670},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":672,"activeCount":71},[],{"intervention":281,"totalTrials":67,"cells":674},{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":679,"PHASE3":681,"PHASE4":683,"NA":689},{"trials":676,"activeCount":71},[],{"trials":678,"activeCount":71},[],{"trials":680,"activeCount":71},[],{"trials":682,"activeCount":71},[],{"trials":684,"activeCount":71},[685],{"nctId":255,"briefTitle":256,"status":188,"phases":686,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":687,"interventions":688},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":690,"activeCount":71},[],{"intervention":282,"totalTrials":67,"cells":692},{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":699,"PHASE4":701,"NA":707},{"trials":694,"activeCount":71},[],{"trials":696,"activeCount":71},[],{"trials":698,"activeCount":71},[],{"trials":700,"activeCount":71},[],{"trials":702,"activeCount":71},[703],{"nctId":255,"briefTitle":256,"status":188,"phases":704,"primaryCompletion":258,"completion":258,"start":259,"enrollment":260,"conditions":705,"interventions":706},[63],[17,262,263],[265,266,267,268,229,269,270,271,272,273,274,275,276,277,278,279,280,281,282],{"trials":708,"activeCount":71},[],{"intervention":710,"totalTrials":67,"cells":711},"One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000,",{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":720,"NA":733},{"trials":713,"activeCount":71},[],{"trials":715,"activeCount":71},[],{"trials":717,"activeCount":71},[],{"trials":719,"activeCount":71},[],{"trials":721,"activeCount":71},[722],{"nctId":723,"briefTitle":724,"status":202,"phases":725,"primaryCompletion":726,"completion":727,"start":728,"enrollment":729,"conditions":730,"interventions":732},"NCT05545514","Individualized Homeopathy to Reduce the Use of Antibiotics in Women With Recurrent Uncomplicated Urinary Tract Infections",[63],"2025-01-30","2026-01-31","2023-03-15",220,[731],"Urinary Tract Infection Chronic",[710],{"trials":734,"activeCount":71},[],{"intervention":736,"totalTrials":67,"cells":737},"Propofol \u002F Remifentanil",{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":744,"PHASE4":746,"NA":760},{"trials":739,"activeCount":71},[],{"trials":741,"activeCount":71},[],{"trials":743,"activeCount":71},[],{"trials":745,"activeCount":71},[],{"trials":747,"activeCount":71},[748],{"nctId":749,"briefTitle":750,"status":188,"phases":751,"primaryCompletion":752,"completion":753,"start":754,"enrollment":755,"conditions":756,"interventions":758},"NCT01720615","Detection of Consciousness by EEG and Auditory Evoked Potentials",[63],"2001-11","2003-04","2001-01",80,[24,757],"Electroencephalography\u002F Drug Effect",[736,759],"Sevoflurane \u002F Remifentanil",{"trials":761,"activeCount":71},[],{"intervention":759,"totalTrials":67,"cells":763},{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":772,"NA":778},{"trials":765,"activeCount":71},[],{"trials":767,"activeCount":71},[],{"trials":769,"activeCount":71},[],{"trials":771,"activeCount":71},[],{"trials":773,"activeCount":71},[774],{"nctId":749,"briefTitle":750,"status":188,"phases":775,"primaryCompletion":752,"completion":753,"start":754,"enrollment":755,"conditions":776,"interventions":777},[63],[24,757],[736,759],{"trials":779,"activeCount":71},[],{"intervention":781,"totalTrials":67,"cells":782},"Human albumin",{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":789,"PHASE4":791,"NA":804},{"trials":784,"activeCount":71},[],{"trials":786,"activeCount":71},[],{"trials":788,"activeCount":71},[],{"trials":790,"activeCount":71},[],{"trials":792,"activeCount":71},[793],{"nctId":794,"briefTitle":795,"status":188,"phases":796,"primaryCompletion":797,"completion":798,"start":799,"enrollment":800,"conditions":801,"interventions":803},"NCT03167645","SUbstition of PERioperative Albumin Deficiency Disorders",[63],"2019-12-21","2021-04-21","2017-06-19",600,[802],"Hypoalbuminemia",[781],{"trials":805,"activeCount":71},[],{"intervention":807,"totalTrials":67,"cells":808},"Donepezil",{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":815,"PHASE4":817,"NA":828},{"trials":810,"activeCount":71},[],{"trials":812,"activeCount":71},[],{"trials":814,"activeCount":71},[],{"trials":816,"activeCount":71},[],{"trials":818,"activeCount":71},[819],{"nctId":820,"briefTitle":821,"status":188,"phases":822,"completion":332,"start":823,"enrollment":824,"conditions":825,"interventions":827},"NCT00220896","Prevention of Postoperative Delirium With Donepezil",[63],"2006-01",37,[826],"Cognitively Normal Elderly Individuals",[807],{"trials":829,"activeCount":71},[],{"intervention":197,"totalTrials":67,"cells":831},{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":838,"PHASE4":840,"NA":846},{"trials":833,"activeCount":71},[],{"trials":835,"activeCount":71},[],{"trials":837,"activeCount":71},[],{"trials":839,"activeCount":71},[],{"trials":841,"activeCount":71},[842],{"nctId":186,"briefTitle":187,"status":188,"phases":843,"completion":190,"start":191,"enrollment":192,"conditions":844,"interventions":845},[63],[194],[37,196,197,198],{"trials":847,"activeCount":71},[],{"intervention":208,"totalTrials":67,"cells":849},{"EARLY_PHASE1":850,"PHASE1":852,"PHASE2":854,"PHASE3":856,"PHASE4":858,"NA":864},{"trials":851,"activeCount":71},[],{"trials":853,"activeCount":71},[],{"trials":855,"activeCount":71},[],{"trials":857,"activeCount":71},[],{"trials":859,"activeCount":71},[860],{"nctId":200,"briefTitle":201,"status":202,"phases":861,"completion":204,"start":204,"enrollment":205,"conditions":862,"interventions":863},[63],[194],[37,208],{"trials":865,"activeCount":71},[],{"intervention":867,"totalTrials":67,"cells":868},"antibiotic",{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":875,"PHASE4":877,"NA":890},{"trials":870,"activeCount":71},[],{"trials":872,"activeCount":71},[],{"trials":874,"activeCount":71},[],{"trials":876,"activeCount":71},[],{"trials":878,"activeCount":71},[879],{"nctId":880,"briefTitle":881,"status":188,"phases":882,"primaryCompletion":883,"completion":884,"start":885,"enrollment":886,"conditions":887,"interventions":889},"NCT02436083","Antibiotics in Free Flaps Reconstructions",[63],"2012-06","2014-12","2007-07",350,[888],"Postoperative Infection",[867],{"trials":891,"activeCount":71},[],{"intervention":893,"totalTrials":67,"cells":894},"Prezista",{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":901,"PHASE4":918,"NA":920},{"trials":896,"activeCount":71},[],{"trials":898,"activeCount":71},[],{"trials":900,"activeCount":71},[],{"trials":902,"activeCount":71},[903],{"nctId":904,"briefTitle":905,"status":188,"phases":906,"primaryCompletion":907,"completion":907,"start":908,"enrollment":909,"conditions":910,"interventions":912},"NCT02486133","Dual Therapy With Boosted Darunavir + Dolutegravir",[62],"2018-05-31","2015-07",269,[911],"HIV-Infection",[893,913,914,915,916,917],"Norvir","Tivicay","Truvada","Kivexa","Descovy",{"trials":919,"activeCount":71},[],{"trials":921,"activeCount":71},[],{"intervention":913,"totalTrials":67,"cells":923},{"EARLY_PHASE1":924,"PHASE1":926,"PHASE2":928,"PHASE3":930,"PHASE4":936,"NA":938},{"trials":925,"activeCount":71},[],{"trials":927,"activeCount":71},[],{"trials":929,"activeCount":71},[],{"trials":931,"activeCount":71},[932],{"nctId":904,"briefTitle":905,"status":188,"phases":933,"primaryCompletion":907,"completion":907,"start":908,"enrollment":909,"conditions":934,"interventions":935},[62],[911],[893,913,914,915,916,917],{"trials":937,"activeCount":71},[],{"trials":939,"activeCount":71},[],{"intervention":914,"totalTrials":67,"cells":941},{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":946,"PHASE3":948,"PHASE4":954,"NA":956},{"trials":943,"activeCount":71},[],{"trials":945,"activeCount":71},[],{"trials":947,"activeCount":71},[],{"trials":949,"activeCount":71},[950],{"nctId":904,"briefTitle":905,"status":188,"phases":951,"primaryCompletion":907,"completion":907,"start":908,"enrollment":909,"conditions":952,"interventions":953},[62],[911],[893,913,914,915,916,917],{"trials":955,"activeCount":71},[],{"trials":957,"activeCount":71},[],{"intervention":915,"totalTrials":67,"cells":959},{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":966,"PHASE4":972,"NA":974},{"trials":961,"activeCount":71},[],{"trials":963,"activeCount":71},[],{"trials":965,"activeCount":71},[],{"trials":967,"activeCount":71},[968],{"nctId":904,"briefTitle":905,"status":188,"phases":969,"primaryCompletion":907,"completion":907,"start":908,"enrollment":909,"conditions":970,"interventions":971},[62],[911],[893,913,914,915,916,917],{"trials":973,"activeCount":71},[],{"trials":975,"activeCount":71},[],{"intervention":916,"totalTrials":67,"cells":977},{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":984,"PHASE4":990,"NA":992},{"trials":979,"activeCount":71},[],{"trials":981,"activeCount":71},[],{"trials":983,"activeCount":71},[],{"trials":985,"activeCount":71},[986],{"nctId":904,"briefTitle":905,"status":188,"phases":987,"primaryCompletion":907,"completion":907,"start":908,"enrollment":909,"conditions":988,"interventions":989},[62],[911],[893,913,914,915,916,917],{"trials":991,"activeCount":71},[],{"trials":993,"activeCount":71},[],{"intervention":917,"totalTrials":67,"cells":995},{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1008,"NA":1010},{"trials":997,"activeCount":71},[],{"trials":999,"activeCount":71},[],{"trials":1001,"activeCount":71},[],{"trials":1003,"activeCount":71},[1004],{"nctId":904,"briefTitle":905,"status":188,"phases":1005,"primaryCompletion":907,"completion":907,"start":908,"enrollment":909,"conditions":1006,"interventions":1007},[62],[911],[893,913,914,915,916,917],{"trials":1009,"activeCount":71},[],{"trials":1011,"activeCount":71},[],{"intervention":1013,"totalTrials":67,"cells":1014},"Berinert",{"EARLY_PHASE1":1015,"PHASE1":1017,"PHASE2":1019,"PHASE3":1021,"PHASE4":1037,"NA":1039},{"trials":1016,"activeCount":71},[],{"trials":1018,"activeCount":71},[],{"trials":1020,"activeCount":71},[],{"trials":1022,"activeCount":71},[1023],{"nctId":1024,"briefTitle":1025,"status":188,"phases":1026,"primaryCompletion":1027,"completion":1028,"start":1029,"enrollment":1030,"conditions":1031,"interventions":1033},"NCT01843530","Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema",[62],"2018-10-05","2019-09-30","2013-11",31,[1032],"Acute ACE-induced Angioedema",[1013,1034,1035,1036],"Clemastin","Cortisone acetate","NaCl",{"trials":1038,"activeCount":71},[],{"trials":1040,"activeCount":71},[],{"intervention":1034,"totalTrials":67,"cells":1042},{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1049,"PHASE4":1055,"NA":1057},{"trials":1044,"activeCount":71},[],{"trials":1046,"activeCount":71},[],{"trials":1048,"activeCount":71},[],{"trials":1050,"activeCount":71},[1051],{"nctId":1024,"briefTitle":1025,"status":188,"phases":1052,"primaryCompletion":1027,"completion":1028,"start":1029,"enrollment":1030,"conditions":1053,"interventions":1054},[62],[1032],[1013,1034,1035,1036],{"trials":1056,"activeCount":71},[],{"trials":1058,"activeCount":71},[],{"intervention":1035,"totalTrials":67,"cells":1060},{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1067,"PHASE4":1073,"NA":1075},{"trials":1062,"activeCount":71},[],{"trials":1064,"activeCount":71},[],{"trials":1066,"activeCount":71},[],{"trials":1068,"activeCount":71},[1069],{"nctId":1024,"briefTitle":1025,"status":188,"phases":1070,"primaryCompletion":1027,"completion":1028,"start":1029,"enrollment":1030,"conditions":1071,"interventions":1072},[62],[1032],[1013,1034,1035,1036],{"trials":1074,"activeCount":71},[],{"trials":1076,"activeCount":71},[],{"intervention":1036,"totalTrials":67,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1085,"PHASE4":1091,"NA":1093},{"trials":1080,"activeCount":71},[],{"trials":1082,"activeCount":71},[],{"trials":1084,"activeCount":71},[],{"trials":1086,"activeCount":71},[1087],{"nctId":1024,"briefTitle":1025,"status":188,"phases":1088,"primaryCompletion":1027,"completion":1028,"start":1029,"enrollment":1030,"conditions":1089,"interventions":1090},[62],[1032],[1013,1034,1035,1036],{"trials":1092,"activeCount":71},[],{"trials":1094,"activeCount":71},[],{"intervention":1096,"totalTrials":67,"cells":1097},"Sorafenib+Pazopanib",{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1104,"PHASE4":1117,"NA":1119},{"trials":1099,"activeCount":71},[],{"trials":1101,"activeCount":71},[],{"trials":1103,"activeCount":71},[],{"trials":1105,"activeCount":71},[1106],{"nctId":1107,"briefTitle":1108,"status":188,"phases":1109,"primaryCompletion":1110,"start":1111,"enrollment":1112,"conditions":1113,"interventions":1115},"NCT01613846","Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced \u002F Metastatic Renal Cell Carcinoma (SWITCH-II)",[62],"2016-10-30","2012-05",544,[1114],"Renal Cell Carcinoma",[1096,1116],"Pazopanib+Sorafenib",{"trials":1118,"activeCount":71},[],{"trials":1120,"activeCount":71},[],{"intervention":1116,"totalTrials":67,"cells":1122},{"EARLY_PHASE1":1123,"PHASE1":1125,"PHASE2":1127,"PHASE3":1129,"PHASE4":1135,"NA":1137},{"trials":1124,"activeCount":71},[],{"trials":1126,"activeCount":71},[],{"trials":1128,"activeCount":71},[],{"trials":1130,"activeCount":71},[1131],{"nctId":1107,"briefTitle":1108,"status":188,"phases":1132,"primaryCompletion":1110,"start":1111,"enrollment":1112,"conditions":1133,"interventions":1134},[62],[1114],[1096,1116],{"trials":1136,"activeCount":71},[],{"trials":1138,"activeCount":71},[],{"intervention":251,"totalTrials":67,"cells":1140},{"EARLY_PHASE1":1141,"PHASE1":1143,"PHASE2":1145,"PHASE3":1147,"PHASE4":1153,"NA":1155},{"trials":1142,"activeCount":71},[],{"trials":1144,"activeCount":71},[],{"trials":1146,"activeCount":71},[],{"trials":1148,"activeCount":71},[1149],{"nctId":241,"briefTitle":242,"status":188,"phases":1150,"primaryCompletion":244,"start":245,"enrollment":246,"conditions":1151,"interventions":1152},[62],[248],[250,251],{"trials":1154,"activeCount":71},[],{"trials":1156,"activeCount":71},[],{"intervention":1158,"totalTrials":67,"cells":1159},"chemotherapy",{"EARLY_PHASE1":1160,"PHASE1":1162,"PHASE2":1164,"PHASE3":1166,"PHASE4":1177,"NA":1179},{"trials":1161,"activeCount":71},[],{"trials":1163,"activeCount":71},[],{"trials":1165,"activeCount":71},[],{"trials":1167,"activeCount":71},[1168],{"nctId":1169,"briefTitle":1170,"status":1171,"phases":1172,"start":1173,"enrollment":71,"conditions":1174,"interventions":1175},"NCT00403182","Chemotherapy and Hormone Therapy as First-Line Therapy in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer","WITHDRAWN",[62],"2006-05",[15],[1158,1176],"letrozole",{"trials":1178,"activeCount":71},[],{"trials":1180,"activeCount":71},[],{"intervention":1176,"totalTrials":67,"cells":1182},{"EARLY_PHASE1":1183,"PHASE1":1185,"PHASE2":1187,"PHASE3":1189,"PHASE4":1195,"NA":1197},{"trials":1184,"activeCount":71},[],{"trials":1186,"activeCount":71},[],{"trials":1188,"activeCount":71},[],{"trials":1190,"activeCount":71},[1191],{"nctId":1169,"briefTitle":1170,"status":1171,"phases":1192,"start":1173,"enrollment":71,"conditions":1193,"interventions":1194},[62],[15],[1158,1176],{"trials":1196,"activeCount":71},[],{"trials":1198,"activeCount":71},[],{"intervention":1200,"totalTrials":1201,"cells":1202},"oxaliplatin",3,{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1247,"PHASE4":1249,"NA":1251},{"trials":1204,"activeCount":71},[],{"trials":1206,"activeCount":71},[],{"trials":1208,"activeCount":71},[1209,1224,1237],{"nctId":1210,"briefTitle":1211,"status":188,"phases":1212,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":119,"conditions":1215,"interventions":1217},"NCT02287129","Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction",[61],"2020-08-07","2014-12-05",[1216],"Adenocarcinoma of the Esophagogastric Junction",[1218,1219,1220,1221,1222,1223],"Oxaliplatin","Epirubicin","Capecitabine","5-FU","Carboplatin","Paclitaxel",{"nctId":1225,"briefTitle":1226,"status":202,"phases":1227,"primaryCompletion":1228,"completion":1229,"start":1230,"enrollment":1231,"conditions":1232,"interventions":1234},"NCT00425425","Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer",[60,61],"2010-05","2015-05","2006-07",43,[1233],"Esophageal Cancer",[1235,1236,1200],"cetuximab","fluorouracil",{"nctId":1238,"briefTitle":1239,"status":188,"phases":1240,"completion":1241,"start":1173,"enrollment":1242,"conditions":1243,"interventions":1245},"NCT00425841","Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer",[61],"2009-12",29,[1244],"Pancreatic Cancer",[1246,1200],"gemcitabine hydrochloride",{"trials":1248,"activeCount":71},[],{"trials":1250,"activeCount":71},[],{"trials":1252,"activeCount":71},[],{"intervention":1254,"totalTrials":1201,"cells":1255},"cyclophosphamide",{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1273,"PHASE3":1302,"PHASE4":1304,"NA":1306},{"trials":1257,"activeCount":71},[],{"trials":1259,"activeCount":71},[1260],{"nctId":1261,"briefTitle":1262,"status":188,"phases":1263,"primaryCompletion":1264,"completion":1265,"start":884,"enrollment":230,"conditions":1266,"interventions":1268},"NCT02276300","HER2-Peptide Vaccination of Patients With Solid Tumors",[60],"2017-07-18","2018-07-13",[1267,15],"Gastric Cancer",[1269,1270,1271,1272],"Cyclophosphamide","Sargramostim","HER2-Peptid-Vakzine","Imiquimod",{"trials":1274,"activeCount":71},[1275,1289],{"nctId":1276,"briefTitle":1277,"status":202,"phases":1278,"start":1279,"enrollment":1280,"conditions":1281,"interventions":1282},"NCT00398489","Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery",[61],"2006-10",94,[15],[1283,1284,1254,1285,1286,1287,1288],"trastuzumab","anastrozole","docetaxel","epirubicin hydrochloride","goserelin acetate","tamoxifen citrate",{"nctId":1290,"briefTitle":1291,"status":202,"phases":1292,"primaryCompletion":1293,"completion":1294,"start":1295,"enrollment":1296,"conditions":1297,"interventions":1299},"NCT00397800","Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma",[60,61],"2008-05","2013-05","2005-06",12,[1298],"Lymphoma",[1300,1254,1301],"rituximab","fludarabine phosphate",{"trials":1303,"activeCount":71},[],{"trials":1305,"activeCount":71},[],{"trials":1307,"activeCount":71},[],{"intervention":1309,"totalTrials":1201,"cells":1310},"Oral Insulin",{"EARLY_PHASE1":1311,"PHASE1":1313,"PHASE2":1315,"PHASE3":1344,"PHASE4":1346,"NA":1348},{"trials":1312,"activeCount":71},[],{"trials":1314,"activeCount":71},[],{"trials":1316,"activeCount":71},[1317,1326,1335],{"nctId":1318,"briefTitle":1319,"status":188,"phases":1320,"primaryCompletion":1321,"completion":1321,"start":1322,"enrollment":1323,"conditions":1324,"interventions":1325},"NCT02547519","Pre-POINT-Early Study",[61],"2017-12","2015-08",44,[30],[1309],{"nctId":1327,"briefTitle":1328,"status":188,"phases":1329,"primaryCompletion":1330,"completion":1330,"start":1331,"enrollment":729,"conditions":1332,"interventions":1334},"NCT02620072","Fr1da Insulin Intervention",[61],"2024-09-30","2015-12-11",[1333],"Stage 1 Diabetes Mellitus, Type 1",[1309],{"nctId":1336,"briefTitle":1337,"status":188,"phases":1338,"primaryCompletion":1339,"completion":1339,"start":1340,"enrollment":1341,"conditions":1342,"interventions":1343},"NCT03364868","GPPAD-POInT (Global Platform of Autoimmune Diabetes - Primary Oral Insulin Trial)",[61],"2024-06-28","2018-02-07",1050,[30],[1309],{"trials":1345,"activeCount":71},[],{"trials":1347,"activeCount":71},[],{"trials":1349,"activeCount":71},[],{"intervention":1220,"totalTrials":230,"cells":1351},{"EARLY_PHASE1":1352,"PHASE1":1354,"PHASE2":1369,"PHASE3":1375,"PHASE4":1377,"NA":1379},{"trials":1353,"activeCount":71},[],{"trials":1355,"activeCount":71},[1356],{"nctId":1357,"briefTitle":1358,"status":188,"phases":1359,"primaryCompletion":1360,"completion":1361,"start":1362,"enrollment":1363,"conditions":1364,"interventions":1365},"NCT00601510","Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer",[60],"2011-01","2012-01","2007-11",38,[1267],[1366,1367,1368],"capecitabine","cisplatin","imatinib mesylate",{"trials":1370,"activeCount":71},[1371],{"nctId":1210,"briefTitle":1211,"status":188,"phases":1372,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":119,"conditions":1373,"interventions":1374},[61],[1216],[1218,1219,1220,1221,1222,1223],{"trials":1376,"activeCount":71},[],{"trials":1378,"activeCount":71},[],{"trials":1380,"activeCount":71},[],{"intervention":1368,"totalTrials":230,"cells":1382},{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1391,"PHASE3":1401,"PHASE4":1403,"NA":1405},{"trials":1384,"activeCount":71},[],{"trials":1386,"activeCount":71},[1387],{"nctId":1357,"briefTitle":1358,"status":188,"phases":1388,"primaryCompletion":1360,"completion":1361,"start":1362,"enrollment":1363,"conditions":1389,"interventions":1390},[60],[1267],[1366,1367,1368],{"trials":1392,"activeCount":71},[1393],{"nctId":1394,"briefTitle":1395,"status":188,"phases":1396,"start":1397,"enrollment":246,"conditions":1398,"interventions":1400},"NCT00112632","Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor",[61],"2005-02",[1399],"Gastrointestinal Stromal Tumor",[1368],{"trials":1402,"activeCount":71},[],{"trials":1404,"activeCount":71},[],{"trials":1406,"activeCount":71},[],{"intervention":1408,"totalTrials":230,"cells":1409},"everolimus",{"EARLY_PHASE1":1410,"PHASE1":1412,"PHASE2":1414,"PHASE3":1435,"PHASE4":1437,"NA":1439},{"trials":1411,"activeCount":71},[],{"trials":1413,"activeCount":71},[],{"trials":1415,"activeCount":71},[1416,1425],{"nctId":1417,"briefTitle":1418,"status":1419,"phases":1420,"primaryCompletion":1421,"completion":1422,"start":1293,"enrollment":215,"conditions":1423,"interventions":1424},"NCT00727207","Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy","TERMINATED",[61],"2011-05","2014-09",[1298],[1408],{"nctId":1426,"briefTitle":1427,"status":188,"phases":1428,"primaryCompletion":883,"start":1429,"enrollment":246,"conditions":1430,"interventions":1432},"NCT00762632","Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia",[60,61],"2007-12",[1431],"Acute Myeloid Leukemia",[1433,1434],"NILOTINIB","EVEROLIMUS",{"trials":1436,"activeCount":71},[],{"trials":1438,"activeCount":71},[],{"trials":1440,"activeCount":71},[],{"intervention":1219,"totalTrials":67,"cells":1442},{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1447,"PHASE3":1453,"PHASE4":1455,"NA":1457},{"trials":1444,"activeCount":71},[],{"trials":1446,"activeCount":71},[],{"trials":1448,"activeCount":71},[1449],{"nctId":1210,"briefTitle":1211,"status":188,"phases":1450,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":119,"conditions":1451,"interventions":1452},[61],[1216],[1218,1219,1220,1221,1222,1223],{"trials":1454,"activeCount":71},[],{"trials":1456,"activeCount":71},[],{"trials":1458,"activeCount":71},[],{"intervention":1221,"totalTrials":67,"cells":1460},{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1465,"PHASE3":1471,"PHASE4":1473,"NA":1475},{"trials":1462,"activeCount":71},[],{"trials":1464,"activeCount":71},[],{"trials":1466,"activeCount":71},[1467],{"nctId":1210,"briefTitle":1211,"status":188,"phases":1468,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":119,"conditions":1469,"interventions":1470},[61],[1216],[1218,1219,1220,1221,1222,1223],{"trials":1472,"activeCount":71},[],{"trials":1474,"activeCount":71},[],{"trials":1476,"activeCount":71},[],{"intervention":1222,"totalTrials":67,"cells":1478},{"EARLY_PHASE1":1479,"PHASE1":1481,"PHASE2":1483,"PHASE3":1489,"PHASE4":1491,"NA":1493},{"trials":1480,"activeCount":71},[],{"trials":1482,"activeCount":71},[],{"trials":1484,"activeCount":71},[1485],{"nctId":1210,"briefTitle":1211,"status":188,"phases":1486,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":119,"conditions":1487,"interventions":1488},[61],[1216],[1218,1219,1220,1221,1222,1223],{"trials":1490,"activeCount":71},[],{"trials":1492,"activeCount":71},[],{"trials":1494,"activeCount":71},[],{"intervention":1223,"totalTrials":67,"cells":1496},{"EARLY_PHASE1":1497,"PHASE1":1499,"PHASE2":1501,"PHASE3":1507,"PHASE4":1509,"NA":1511},{"trials":1498,"activeCount":71},[],{"trials":1500,"activeCount":71},[],{"trials":1502,"activeCount":71},[1503],{"nctId":1210,"briefTitle":1211,"status":188,"phases":1504,"primaryCompletion":1213,"completion":1213,"start":1214,"enrollment":119,"conditions":1505,"interventions":1506},[61],[1216],[1218,1219,1220,1221,1222,1223],{"trials":1508,"activeCount":71},[],{"trials":1510,"activeCount":71},[],{"trials":1512,"activeCount":71},[],{"intervention":1283,"totalTrials":67,"cells":1514},{"EARLY_PHASE1":1515,"PHASE1":1517,"PHASE2":1519,"PHASE3":1525,"PHASE4":1527,"NA":1529},{"trials":1516,"activeCount":71},[],{"trials":1518,"activeCount":71},[],{"trials":1520,"activeCount":71},[1521],{"nctId":1276,"briefTitle":1277,"status":202,"phases":1522,"start":1279,"enrollment":1280,"conditions":1523,"interventions":1524},[61],[15],[1283,1284,1254,1285,1286,1287,1288],{"trials":1526,"activeCount":71},[],{"trials":1528,"activeCount":71},[],{"trials":1530,"activeCount":71},[],{"intervention":1284,"totalTrials":67,"cells":1532},{"EARLY_PHASE1":1533,"PHASE1":1535,"PHASE2":1537,"PHASE3":1543,"PHASE4":1545,"NA":1547},{"trials":1534,"activeCount":71},[],{"trials":1536,"activeCount":71},[],{"trials":1538,"activeCount":71},[1539],{"nctId":1276,"briefTitle":1277,"status":202,"phases":1540,"start":1279,"enrollment":1280,"conditions":1541,"interventions":1542},[61],[15],[1283,1284,1254,1285,1286,1287,1288],{"trials":1544,"activeCount":71},[],{"trials":1546,"activeCount":71},[],{"trials":1548,"activeCount":71},[],{"intervention":1285,"totalTrials":67,"cells":1550},{"EARLY_PHASE1":1551,"PHASE1":1553,"PHASE2":1555,"PHASE3":1561,"PHASE4":1563,"NA":1565},{"trials":1552,"activeCount":71},[],{"trials":1554,"activeCount":71},[],{"trials":1556,"activeCount":71},[1557],{"nctId":1276,"briefTitle":1277,"status":202,"phases":1558,"start":1279,"enrollment":1280,"conditions":1559,"interventions":1560},[61],[15],[1283,1284,1254,1285,1286,1287,1288],{"trials":1562,"activeCount":71},[],{"trials":1564,"activeCount":71},[],{"trials":1566,"activeCount":71},[],{"intervention":1286,"totalTrials":67,"cells":1568},{"EARLY_PHASE1":1569,"PHASE1":1571,"PHASE2":1573,"PHASE3":1579,"PHASE4":1581,"NA":1583},{"trials":1570,"activeCount":71},[],{"trials":1572,"activeCount":71},[],{"trials":1574,"activeCount":71},[1575],{"nctId":1276,"briefTitle":1277,"status":202,"phases":1576,"start":1279,"enrollment":1280,"conditions":1577,"interventions":1578},[61],[15],[1283,1284,1254,1285,1286,1287,1288],{"trials":1580,"activeCount":71},[],{"trials":1582,"activeCount":71},[],{"trials":1584,"activeCount":71},[],{"intervention":1287,"totalTrials":67,"cells":1586},{"EARLY_PHASE1":1587,"PHASE1":1589,"PHASE2":1591,"PHASE3":1597,"PHASE4":1599,"NA":1601},{"trials":1588,"activeCount":71},[],{"trials":1590,"activeCount":71},[],{"trials":1592,"activeCount":71},[1593],{"nctId":1276,"briefTitle":1277,"status":202,"phases":1594,"start":1279,"enrollment":1280,"conditions":1595,"interventions":1596},[61],[15],[1283,1284,1254,1285,1286,1287,1288],{"trials":1598,"activeCount":71},[],{"trials":1600,"activeCount":71},[],{"trials":1602,"activeCount":71},[],{"intervention":1288,"totalTrials":67,"cells":1604},{"EARLY_PHASE1":1605,"PHASE1":1607,"PHASE2":1609,"PHASE3":1615,"PHASE4":1617,"NA":1619},{"trials":1606,"activeCount":71},[],{"trials":1608,"activeCount":71},[],{"trials":1610,"activeCount":71},[1611],{"nctId":1276,"briefTitle":1277,"status":202,"phases":1612,"start":1279,"enrollment":1280,"conditions":1613,"interventions":1614},[61],[15],[1283,1284,1254,1285,1286,1287,1288],{"trials":1616,"activeCount":71},[],{"trials":1618,"activeCount":71},[],{"trials":1620,"activeCount":71},[],{"intervention":1622,"totalTrials":67,"cells":1623},"Lovastatin",{"EARLY_PHASE1":1624,"PHASE1":1626,"PHASE2":1628,"PHASE3":1643,"PHASE4":1645,"NA":1647},{"trials":1625,"activeCount":71},[],{"trials":1627,"activeCount":71},[],{"trials":1629,"activeCount":71},[1630],{"nctId":1631,"briefTitle":1632,"status":1419,"phases":1633,"primaryCompletion":1634,"completion":1635,"start":1636,"enrollment":1637,"conditions":1638,"interventions":1641},"NCT03504501","Synaptic Plasticity and Cognitive Function in RASopathies",[61],"2023-02-09","2023-10-31","2019-03-22",16,[1639,1640],"Impaired Synaptic Plasticity","Impaired Cognition",[1622,1642],"Lamotrigine",{"trials":1644,"activeCount":71},[],{"trials":1646,"activeCount":71},[],{"trials":1648,"activeCount":71},[],{"intervention":1642,"totalTrials":67,"cells":1650},{"EARLY_PHASE1":1651,"PHASE1":1653,"PHASE2":1655,"PHASE3":1661,"PHASE4":1663,"NA":1665},{"trials":1652,"activeCount":71},[],{"trials":1654,"activeCount":71},[],{"trials":1656,"activeCount":71},[1657],{"nctId":1631,"briefTitle":1632,"status":1419,"phases":1658,"primaryCompletion":1634,"completion":1635,"start":1636,"enrollment":1637,"conditions":1659,"interventions":1660},[61],[1639,1640],[1622,1642],{"trials":1662,"activeCount":71},[],{"trials":1664,"activeCount":71},[],{"trials":1666,"activeCount":71},[],{"intervention":1668,"totalTrials":67,"cells":1669},"MabThera",{"EARLY_PHASE1":1670,"PHASE1":1672,"PHASE2":1674,"PHASE3":1688,"PHASE4":1690,"NA":1692},{"trials":1671,"activeCount":71},[],{"trials":1673,"activeCount":71},[],{"trials":1675,"activeCount":71},[1676],{"nctId":1677,"briefTitle":1678,"status":1419,"phases":1679,"completion":1680,"start":1429,"enrollment":1681,"conditions":1682,"interventions":1687},"NCT00568477","Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation",[61],"2010-12",200,[1683,1684,1685,1686],"Grafting","Renal Transplantation","Transplantation, Kidney","Chronic Allograft Nephropathy",[1668],{"trials":1689,"activeCount":71},[],{"trials":1691,"activeCount":71},[],{"trials":1693,"activeCount":71},[],{"intervention":1695,"totalTrials":67,"cells":1696},"Icatibant",{"EARLY_PHASE1":1697,"PHASE1":1699,"PHASE2":1701,"PHASE3":1711,"PHASE4":1713,"NA":1715},{"trials":1698,"activeCount":71},[],{"trials":1700,"activeCount":71},[],{"trials":1702,"activeCount":71},[1703],{"nctId":1704,"briefTitle":1705,"status":188,"phases":1706,"conditions":1707,"interventions":1709},"NCT01154361","AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study",[61],[1708],"Angioedema",[1695,1710],"Cortisone + Clemastin",{"trials":1712,"activeCount":71},[],{"trials":1714,"activeCount":71},[],{"trials":1716,"activeCount":71},[],{"intervention":1710,"totalTrials":67,"cells":1718},{"EARLY_PHASE1":1719,"PHASE1":1721,"PHASE2":1723,"PHASE3":1729,"PHASE4":1731,"NA":1733},{"trials":1720,"activeCount":71},[],{"trials":1722,"activeCount":71},[],{"trials":1724,"activeCount":71},[1725],{"nctId":1704,"briefTitle":1705,"status":188,"phases":1726,"conditions":1727,"interventions":1728},[61],[1708],[1695,1710],{"trials":1730,"activeCount":71},[],{"trials":1732,"activeCount":71},[],{"trials":1734,"activeCount":71},[],{"intervention":1736,"totalTrials":67,"cells":1737},"Bevacizumab-IRDye800CW",{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1742,"PHASE3":1752,"PHASE4":1754,"NA":1756},{"trials":1739,"activeCount":71},[],{"trials":1741,"activeCount":71},[],{"trials":1743,"activeCount":71},[1744],{"nctId":1745,"briefTitle":1746,"status":1171,"phases":1747,"primaryCompletion":1748,"completion":1748,"start":1749,"enrollment":71,"conditions":1750,"interventions":1751},"NCT05359874","Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW",[61],"2023-03","2021-06",[15],[1736],{"trials":1753,"activeCount":71},[],{"trials":1755,"activeCount":71},[],{"trials":1757,"activeCount":71},[],{"intervention":1235,"totalTrials":67,"cells":1759},{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1764,"PHASE3":1770,"PHASE4":1772,"NA":1774},{"trials":1761,"activeCount":71},[],{"trials":1763,"activeCount":71},[],{"trials":1765,"activeCount":71},[1766],{"nctId":1225,"briefTitle":1226,"status":202,"phases":1767,"primaryCompletion":1228,"completion":1229,"start":1230,"enrollment":1231,"conditions":1768,"interventions":1769},[60,61],[1233],[1235,1236,1200],{"trials":1771,"activeCount":71},[],{"trials":1773,"activeCount":71},[],{"trials":1775,"activeCount":71},[],{"intervention":1236,"totalTrials":67,"cells":1777},{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1782,"PHASE3":1788,"PHASE4":1790,"NA":1792},{"trials":1779,"activeCount":71},[],{"trials":1781,"activeCount":71},[],{"trials":1783,"activeCount":71},[1784],{"nctId":1225,"briefTitle":1226,"status":202,"phases":1785,"primaryCompletion":1228,"completion":1229,"start":1230,"enrollment":1231,"conditions":1786,"interventions":1787},[60,61],[1233],[1235,1236,1200],{"trials":1789,"activeCount":71},[],{"trials":1791,"activeCount":71},[],{"trials":1793,"activeCount":71},[],{"intervention":1795,"totalTrials":67,"cells":1796},"Secukinumab",{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1801,"PHASE3":1814,"PHASE4":1816,"NA":1818},{"trials":1798,"activeCount":71},[],{"trials":1800,"activeCount":71},[],{"trials":1802,"activeCount":71},[1803],{"nctId":1804,"briefTitle":1805,"status":188,"phases":1806,"primaryCompletion":1807,"completion":1808,"start":1809,"enrollment":1810,"conditions":1811,"interventions":1813},"NCT02733094","Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum",[60,61],"2019-09-10","2019-09-19","2016-04",8,[1812],"Pyoderma Gangrenosum",[1795],{"trials":1815,"activeCount":71},[],{"trials":1817,"activeCount":71},[],{"trials":1819,"activeCount":71},[],{"intervention":1821,"totalTrials":67,"cells":1822},"Panobinostat",{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1827,"PHASE3":1839,"PHASE4":1841,"NA":1843},{"trials":1824,"activeCount":71},[],{"trials":1826,"activeCount":71},[],{"trials":1828,"activeCount":71},[1829],{"nctId":1830,"briefTitle":1831,"status":1419,"phases":1832,"primaryCompletion":1833,"start":1834,"enrollment":1835,"conditions":1836,"interventions":1838},"NCT01528501","Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008)",[61],"2013-02","2009-06",28,[1837],"Metastatic Gastric Cancer",[1821],{"trials":1840,"activeCount":71},[],{"trials":1842,"activeCount":71},[],{"trials":1844,"activeCount":71},[],{"intervention":1846,"totalTrials":67,"cells":1847},"intranasal insulin",{"EARLY_PHASE1":1848,"PHASE1":1850,"PHASE2":1852,"PHASE3":1862,"PHASE4":1864,"NA":1866},{"trials":1849,"activeCount":71},[],{"trials":1851,"activeCount":71},[],{"trials":1853,"activeCount":71},[1854],{"nctId":1855,"briefTitle":1856,"status":188,"phases":1857,"primaryCompletion":1858,"completion":1858,"start":1859,"enrollment":1363,"conditions":1860,"interventions":1861},"NCT03182322","PINIT Study: Primary Intranasal Insulin Trial",[61],"2021-06-07","2018-05-25",[30],[1846],{"trials":1863,"activeCount":71},[],{"trials":1865,"activeCount":71},[],{"trials":1867,"activeCount":71},[],{"intervention":1869,"totalTrials":67,"cells":1870},"FBTA05",{"EARLY_PHASE1":1871,"PHASE1":1873,"PHASE2":1875,"PHASE3":1887,"PHASE4":1889,"NA":1891},{"trials":1872,"activeCount":71},[],{"trials":1874,"activeCount":71},[],{"trials":1876,"activeCount":71},[1877],{"nctId":1878,"briefTitle":1879,"status":1171,"phases":1880,"primaryCompletion":1229,"completion":1881,"start":1882,"enrollment":71,"conditions":1883,"interventions":1886},"NCT01138579","Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation",[60,61],"2015-06","2010-08",[1884,1885],"Leukemia","Stem Cell Transplantation",[1869],{"trials":1888,"activeCount":71},[],{"trials":1890,"activeCount":71},[],{"trials":1892,"activeCount":71},[],{"intervention":1894,"totalTrials":67,"cells":1895},"Omalizumab",{"EARLY_PHASE1":1896,"PHASE1":1898,"PHASE2":1900,"PHASE3":1910,"PHASE4":1912,"NA":1914},{"trials":1897,"activeCount":71},[],{"trials":1899,"activeCount":71},[],{"trials":1901,"activeCount":71},[1902],{"nctId":1903,"briefTitle":1904,"status":188,"phases":1905,"conditions":1906,"interventions":1909},"NCT01179529","Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage",[61],[1907,1908],"Atopic Dermatitis","Atopic Eczema",[1894],{"trials":1911,"activeCount":71},[],{"trials":1913,"activeCount":71},[],{"trials":1915,"activeCount":71},[],{"intervention":1300,"totalTrials":67,"cells":1917},{"EARLY_PHASE1":1918,"PHASE1":1920,"PHASE2":1922,"PHASE3":1928,"PHASE4":1930,"NA":1932},{"trials":1919,"activeCount":71},[],{"trials":1921,"activeCount":71},[],{"trials":1923,"activeCount":71},[1924],{"nctId":1290,"briefTitle":1291,"status":202,"phases":1925,"primaryCompletion":1293,"completion":1294,"start":1295,"enrollment":1296,"conditions":1926,"interventions":1927},[60,61],[1298],[1300,1254,1301],{"trials":1929,"activeCount":71},[],{"trials":1931,"activeCount":71},[],{"trials":1933,"activeCount":71},[],{"intervention":1301,"totalTrials":67,"cells":1935},{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1940,"PHASE3":1946,"PHASE4":1948,"NA":1950},{"trials":1937,"activeCount":71},[],{"trials":1939,"activeCount":71},[],{"trials":1941,"activeCount":71},[1942],{"nctId":1290,"briefTitle":1291,"status":202,"phases":1943,"primaryCompletion":1293,"completion":1294,"start":1295,"enrollment":1296,"conditions":1944,"interventions":1945},[60,61],[1298],[1300,1254,1301],{"trials":1947,"activeCount":71},[],{"trials":1949,"activeCount":71},[],{"trials":1951,"activeCount":71},[],{"intervention":1246,"totalTrials":67,"cells":1953},{"EARLY_PHASE1":1954,"PHASE1":1956,"PHASE2":1958,"PHASE3":1964,"PHASE4":1966,"NA":1968},{"trials":1955,"activeCount":71},[],{"trials":1957,"activeCount":71},[],{"trials":1959,"activeCount":71},[1960],{"nctId":1238,"briefTitle":1239,"status":188,"phases":1961,"completion":1241,"start":1173,"enrollment":1242,"conditions":1962,"interventions":1963},[61],[1244],[1246,1200],{"trials":1965,"activeCount":71},[],{"trials":1967,"activeCount":71},[],{"trials":1969,"activeCount":71},[],{"intervention":1433,"totalTrials":67,"cells":1971},{"EARLY_PHASE1":1972,"PHASE1":1974,"PHASE2":1976,"PHASE3":1982,"PHASE4":1984,"NA":1986},{"trials":1973,"activeCount":71},[],{"trials":1975,"activeCount":71},[],{"trials":1977,"activeCount":71},[1978],{"nctId":1426,"briefTitle":1427,"status":188,"phases":1979,"primaryCompletion":883,"start":1429,"enrollment":246,"conditions":1980,"interventions":1981},[60,61],[1431],[1433,1434],{"trials":1983,"activeCount":71},[],{"trials":1985,"activeCount":71},[],{"trials":1987,"activeCount":71},[],{"intervention":1989,"totalTrials":67,"cells":1990},"Nivolumab",{"EARLY_PHASE1":1991,"PHASE1":1993,"PHASE2":1995,"PHASE3":2008,"PHASE4":2010,"NA":2012},{"trials":1992,"activeCount":71},[],{"trials":1994,"activeCount":71},[],{"trials":1996,"activeCount":71},[1997],{"nctId":1998,"briefTitle":1999,"status":202,"phases":2000,"primaryCompletion":2001,"completion":2002,"start":2003,"enrollment":2004,"conditions":2005,"interventions":2007},"NCT03529890","Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder",[61],"2022-04-14","2023-08","2019-02-04",33,[2006],"Urinary Bladder Cancer",[1989],{"trials":2009,"activeCount":71},[],{"trials":2011,"activeCount":71},[],{"trials":2013,"activeCount":71},[],{"intervention":2015,"totalTrials":67,"cells":2016},"Modafinil",{"EARLY_PHASE1":2017,"PHASE1":2019,"PHASE2":2021,"PHASE3":2032,"PHASE4":2034,"NA":2036},{"trials":2018,"activeCount":71},[],{"trials":2020,"activeCount":71},[],{"trials":2022,"activeCount":71},[2023],{"nctId":2024,"briefTitle":2025,"status":1171,"phases":2026,"primaryCompletion":2027,"completion":2027,"start":1293,"enrollment":2028,"conditions":2029,"interventions":2031},"NCT00670813","Enhancing the Therapeutic Efficacy of Sleep Deprivation by Modafinil",[61],"2009-11",30,[2030],"Depression",[2015],{"trials":2033,"activeCount":71},[],{"trials":2035,"activeCount":71},[],{"trials":2037,"activeCount":71},[],{"intervention":2039,"totalTrials":67,"cells":2040},"Apremilast",{"EARLY_PHASE1":2041,"PHASE1":2043,"PHASE2":2045,"PHASE3":2058,"PHASE4":2060,"NA":2062},{"trials":2042,"activeCount":71},[],{"trials":2044,"activeCount":71},[],{"trials":2046,"activeCount":71},[2047],{"nctId":2048,"briefTitle":2049,"status":188,"phases":2050,"primaryCompletion":2051,"completion":2051,"start":2052,"enrollment":1030,"conditions":2053,"interventions":2057},"NCT03160248","An Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular Eczema",[61],"2021-09-15","2017-07-05",[165,2054,2055,2056],"Eczema","Dermatitis Eczema","Nummular Dermatitis",[2039],{"trials":2059,"activeCount":71},[],{"trials":2061,"activeCount":71},[],{"trials":2063,"activeCount":71},[],{"intervention":2065,"totalTrials":67,"cells":2066},"Alcon",{"EARLY_PHASE1":2067,"PHASE1":2069,"PHASE2":2071,"PHASE3":2084,"PHASE4":2086,"NA":2088},{"trials":2068,"activeCount":71},[],{"trials":2070,"activeCount":71},[],{"trials":2072,"activeCount":71},[2073],{"nctId":2074,"briefTitle":2075,"status":188,"phases":2076,"primaryCompletion":2077,"completion":2078,"start":2079,"enrollment":2080,"conditions":2081,"interventions":2083},"NCT04597801","Comparison of Fluorescein-INtra-VItal Microscopy Versus Conventional Frozen Section Diagnosis for intraOperative Histopathological Evaluation",[61],"2022-06-17","2022-08-03","2020-12-30",210,[2082],"Intracranial Tumor",[2065],{"trials":2085,"activeCount":71},[],{"trials":2087,"activeCount":71},[],{"trials":2089,"activeCount":71},[],{"intervention":2091,"totalTrials":67,"cells":2092},"Gemcitabine, Oxaliplatin, Photodynamic therapy",{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2097,"PHASE3":2108,"PHASE4":2110,"NA":2112},{"trials":2094,"activeCount":71},[],{"trials":2096,"activeCount":71},[],{"trials":2098,"activeCount":71},[2099],{"nctId":2100,"briefTitle":2101,"status":1171,"phases":2102,"completion":2103,"start":2104,"enrollment":71,"conditions":2105,"interventions":2107},"NCT00713687","Gemcitabine\u002FOxaliplatin and Photodynamic Therapy in Cholangiocarcinoma",[61],"2011-12","2008-08",[2106],"Cholangiocarcinoma",[2091],{"trials":2109,"activeCount":71},[],{"trials":2111,"activeCount":71},[],{"trials":2113,"activeCount":71},[],{"intervention":1367,"totalTrials":67,"cells":2115},{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2124,"PHASE3":2126,"PHASE4":2128,"NA":2130},{"trials":2117,"activeCount":71},[],{"trials":2119,"activeCount":71},[2120],{"nctId":1357,"briefTitle":1358,"status":188,"phases":2121,"primaryCompletion":1360,"completion":1361,"start":1362,"enrollment":1363,"conditions":2122,"interventions":2123},[60],[1267],[1366,1367,1368],{"trials":2125,"activeCount":71},[],{"trials":2127,"activeCount":71},[],{"trials":2129,"activeCount":71},[],{"trials":2131,"activeCount":71},[],{"intervention":2133,"totalTrials":67,"cells":2134},"Tenofovir disaproxil fumarate\u002Femtricitabine\u002Felvitegravir\u002Fcobicistat",{"EARLY_PHASE1":2135,"PHASE1":2137,"PHASE2":2150,"PHASE3":2152,"PHASE4":2154,"NA":2156},{"trials":2136,"activeCount":71},[],{"trials":2138,"activeCount":71},[2139],{"nctId":2140,"briefTitle":2141,"status":188,"phases":2142,"primaryCompletion":2143,"completion":2143,"start":2144,"enrollment":2028,"conditions":2145,"interventions":2147},"NCT02203461","Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication",[60],"2014-10","2014-07",[2146],"Insulin Resistance",[2133,2148,2149],"Tenofovir disaproxil fumarate\u002Femtricitabine + Lopinavir\u002Fritonavir","Tenofovir disaproxil fumarate\u002Femtricitabine + ritonavir-boosted darunavir",{"trials":2151,"activeCount":71},[],{"trials":2153,"activeCount":71},[],{"trials":2155,"activeCount":71},[],{"trials":2157,"activeCount":71},[],{"intervention":2148,"totalTrials":67,"cells":2159},{"EARLY_PHASE1":2160,"PHASE1":2162,"PHASE2":2168,"PHASE3":2170,"PHASE4":2172,"NA":2174},{"trials":2161,"activeCount":71},[],{"trials":2163,"activeCount":71},[2164],{"nctId":2140,"briefTitle":2141,"status":188,"phases":2165,"primaryCompletion":2143,"completion":2143,"start":2144,"enrollment":2028,"conditions":2166,"interventions":2167},[60],[2146],[2133,2148,2149],{"trials":2169,"activeCount":71},[],{"trials":2171,"activeCount":71},[],{"trials":2173,"activeCount":71},[],{"trials":2175,"activeCount":71},[],{"intervention":2149,"totalTrials":67,"cells":2177},{"EARLY_PHASE1":2178,"PHASE1":2180,"PHASE2":2186,"PHASE3":2188,"PHASE4":2190,"NA":2192},{"trials":2179,"activeCount":71},[],{"trials":2181,"activeCount":71},[2182],{"nctId":2140,"briefTitle":2141,"status":188,"phases":2183,"primaryCompletion":2143,"completion":2143,"start":2144,"enrollment":2028,"conditions":2184,"interventions":2185},[60],[2146],[2133,2148,2149],{"trials":2187,"activeCount":71},[],{"trials":2189,"activeCount":71},[],{"trials":2191,"activeCount":71},[],{"trials":2193,"activeCount":71},[],{"intervention":2195,"totalTrials":67,"cells":2196},"F\u002FTAF",{"EARLY_PHASE1":2197,"PHASE1":2199,"PHASE2":2211,"PHASE3":2213,"PHASE4":2215,"NA":2217},{"trials":2198,"activeCount":71},[],{"trials":2200,"activeCount":71},[2201],{"nctId":2202,"briefTitle":2203,"status":188,"phases":2204,"primaryCompletion":2205,"completion":2205,"start":2206,"enrollment":2028,"conditions":2207,"interventions":2208},"NCT03092206","Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral Medication",[60],"2017-07-28","2017-04-18",[2146],[2195,2209,2210],"E\u002FC\u002FF\u002FTAF","R\u002FF\u002FTAF",{"trials":2212,"activeCount":71},[],{"trials":2214,"activeCount":71},[],{"trials":2216,"activeCount":71},[],{"trials":2218,"activeCount":71},[],{"intervention":2209,"totalTrials":67,"cells":2220},{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2229,"PHASE3":2231,"PHASE4":2233,"NA":2235},{"trials":2222,"activeCount":71},[],{"trials":2224,"activeCount":71},[2225],{"nctId":2202,"briefTitle":2203,"status":188,"phases":2226,"primaryCompletion":2205,"completion":2205,"start":2206,"enrollment":2028,"conditions":2227,"interventions":2228},[60],[2146],[2195,2209,2210],{"trials":2230,"activeCount":71},[],{"trials":2232,"activeCount":71},[],{"trials":2234,"activeCount":71},[],{"trials":2236,"activeCount":71},[],{"intervention":2210,"totalTrials":67,"cells":2238},{"EARLY_PHASE1":2239,"PHASE1":2241,"PHASE2":2247,"PHASE3":2249,"PHASE4":2251,"NA":2253},{"trials":2240,"activeCount":71},[],{"trials":2242,"activeCount":71},[2243],{"nctId":2202,"briefTitle":2203,"status":188,"phases":2244,"primaryCompletion":2205,"completion":2205,"start":2206,"enrollment":2028,"conditions":2245,"interventions":2246},[60],[2146],[2195,2209,2210],{"trials":2248,"activeCount":71},[],{"trials":2250,"activeCount":71},[],{"trials":2252,"activeCount":71},[],{"trials":2254,"activeCount":71},[],{"intervention":2256,"totalTrials":67,"cells":2257},"Wobenzym plus",{"EARLY_PHASE1":2258,"PHASE1":2260,"PHASE2":2281,"PHASE3":2283,"PHASE4":2285,"NA":2287},{"trials":2259,"activeCount":71},[],{"trials":2261,"activeCount":71},[2262],{"nctId":2263,"briefTitle":2264,"status":188,"phases":2265,"primaryCompletion":294,"completion":2266,"start":2267,"enrollment":2268,"conditions":2269,"interventions":2279},"NCT01916408","The Effects of Enzymes and Flavonoids on Inflammation and Coagulation After Marathon",[60],"2014-08","2013-08",160,[2270,2271,2272,2273,2274,2275,2276,2277,2278],"Inflammation","Death, Sudden, Cardiac","Death","Heart Diseases","Cardiovascular Diseases","Pathologic Processes","Death, Sudden","Blood Coagulation Disorders","Respiratory Tract Infections",[2256,2280],"PL 1",{"trials":2282,"activeCount":71},[],{"trials":2284,"activeCount":71},[],{"trials":2286,"activeCount":71},[],{"trials":2288,"activeCount":71},[],{"intervention":2280,"totalTrials":67,"cells":2290},{"EARLY_PHASE1":2291,"PHASE1":2293,"PHASE2":2299,"PHASE3":2301,"PHASE4":2303,"NA":2305},{"trials":2292,"activeCount":71},[],{"trials":2294,"activeCount":71},[2295],{"nctId":2263,"briefTitle":2264,"status":188,"phases":2296,"primaryCompletion":294,"completion":2266,"start":2267,"enrollment":2268,"conditions":2297,"interventions":2298},[60],[2270,2271,2272,2273,2274,2275,2276,2277,2278],[2256,2280],{"trials":2300,"activeCount":71},[],{"trials":2302,"activeCount":71},[],{"trials":2304,"activeCount":71},[],{"trials":2306,"activeCount":71},[],{"intervention":1270,"totalTrials":67,"cells":2308},{"EARLY_PHASE1":2309,"PHASE1":2311,"PHASE2":2317,"PHASE3":2319,"PHASE4":2321,"NA":2323},{"trials":2310,"activeCount":71},[],{"trials":2312,"activeCount":71},[2313],{"nctId":1261,"briefTitle":1262,"status":188,"phases":2314,"primaryCompletion":1264,"completion":1265,"start":884,"enrollment":230,"conditions":2315,"interventions":2316},[60],[1267,15],[1269,1270,1271,1272],{"trials":2318,"activeCount":71},[],{"trials":2320,"activeCount":71},[],{"trials":2322,"activeCount":71},[],{"trials":2324,"activeCount":71},[],{"intervention":1271,"totalTrials":67,"cells":2326},{"EARLY_PHASE1":2327,"PHASE1":2329,"PHASE2":2335,"PHASE3":2337,"PHASE4":2339,"NA":2341},{"trials":2328,"activeCount":71},[],{"trials":2330,"activeCount":71},[2331],{"nctId":1261,"briefTitle":1262,"status":188,"phases":2332,"primaryCompletion":1264,"completion":1265,"start":884,"enrollment":230,"conditions":2333,"interventions":2334},[60],[1267,15],[1269,1270,1271,1272],{"trials":2336,"activeCount":71},[],{"trials":2338,"activeCount":71},[],{"trials":2340,"activeCount":71},[],{"trials":2342,"activeCount":71},[],{"intervention":1272,"totalTrials":67,"cells":2344},{"EARLY_PHASE1":2345,"PHASE1":2347,"PHASE2":2353,"PHASE3":2355,"PHASE4":2357,"NA":2359},{"trials":2346,"activeCount":71},[],{"trials":2348,"activeCount":71},[2349],{"nctId":1261,"briefTitle":1262,"status":188,"phases":2350,"primaryCompletion":1264,"completion":1265,"start":884,"enrollment":230,"conditions":2351,"interventions":2352},[60],[1267,15],[1269,1270,1271,1272],{"trials":2354,"activeCount":71},[],{"trials":2356,"activeCount":71},[],{"trials":2358,"activeCount":71},[],{"trials":2360,"activeCount":71},[],{"intervention":196,"totalTrials":230,"cells":2362},{"EARLY_PHASE1":2363,"PHASE1":2365,"PHASE2":2367,"PHASE3":2369,"PHASE4":2371,"NA":2377},{"trials":2364,"activeCount":71},[],{"trials":2366,"activeCount":71},[],{"trials":2368,"activeCount":71},[],{"trials":2370,"activeCount":71},[],{"trials":2372,"activeCount":71},[2373],{"nctId":186,"briefTitle":187,"status":188,"phases":2374,"completion":190,"start":191,"enrollment":192,"conditions":2375,"interventions":2376},[63],[194],[37,196,197,198],{"trials":2378,"activeCount":71},[2379],{"nctId":2380,"briefTitle":2381,"status":188,"phases":2382,"primaryCompletion":2383,"completion":2383,"start":2384,"enrollment":2385,"conditions":2386,"interventions":2388},"NCT02054468","Rocuronium Dose Finding Study After Single-shot or Steady-state Propofol Anesthesia",[64],"2014-02","2012-03",82,[2387,24],"Neuromuscular Blockade",[2389,2390,196,2391,2391,2391,2391,2391,2391],"Single-Shot Propofol","30min infusion Propofol","Rocuronium",{"intervention":2393,"totalTrials":230,"cells":2394},"Sugammadex",{"EARLY_PHASE1":2395,"PHASE1":2397,"PHASE2":2399,"PHASE3":2401,"PHASE4":2403,"NA":2414},{"trials":2396,"activeCount":71},[],{"trials":2398,"activeCount":71},[],{"trials":2400,"activeCount":71},[],{"trials":2402,"activeCount":71},[],{"trials":2404,"activeCount":71},[2405],{"nctId":2406,"briefTitle":2407,"status":188,"phases":2408,"primaryCompletion":1421,"completion":2409,"start":2410,"enrollment":2411,"conditions":2412,"interventions":2413},"NCT01101139","Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery",[63],"2011-06","2010-04",300,[2387],[2393],{"trials":2415,"activeCount":71},[2416],{"nctId":2417,"briefTitle":2418,"status":188,"phases":2419,"primaryCompletion":2420,"completion":1241,"start":332,"enrollment":224,"conditions":2421,"interventions":2423},"NCT01006720","Sugammadex and Neostigmine at Residual Neuromuscular Blockade",[],"2009-07",[2422],"Residual Neuromuscular Block (TOF-ratio of 0.2)",[2393,2424,2425],"Neostigmine","Saline",{"intervention":2389,"totalTrials":67,"cells":2427},{"EARLY_PHASE1":2428,"PHASE1":2430,"PHASE2":2432,"PHASE3":2434,"PHASE4":2436,"NA":2438},{"trials":2429,"activeCount":71},[],{"trials":2431,"activeCount":71},[],{"trials":2433,"activeCount":71},[],{"trials":2435,"activeCount":71},[],{"trials":2437,"activeCount":71},[],{"trials":2439,"activeCount":71},[2440],{"nctId":2380,"briefTitle":2381,"status":188,"phases":2441,"primaryCompletion":2383,"completion":2383,"start":2384,"enrollment":2385,"conditions":2442,"interventions":2443},[64],[2387,24],[2389,2390,196,2391,2391,2391,2391,2391,2391],{"intervention":2390,"totalTrials":67,"cells":2445},{"EARLY_PHASE1":2446,"PHASE1":2448,"PHASE2":2450,"PHASE3":2452,"PHASE4":2454,"NA":2456},{"trials":2447,"activeCount":71},[],{"trials":2449,"activeCount":71},[],{"trials":2451,"activeCount":71},[],{"trials":2453,"activeCount":71},[],{"trials":2455,"activeCount":71},[],{"trials":2457,"activeCount":71},[2458],{"nctId":2380,"briefTitle":2381,"status":188,"phases":2459,"primaryCompletion":2383,"completion":2383,"start":2384,"enrollment":2385,"conditions":2460,"interventions":2461},[64],[2387,24],[2389,2390,196,2391,2391,2391,2391,2391,2391],{"intervention":2391,"totalTrials":67,"cells":2463},{"EARLY_PHASE1":2464,"PHASE1":2466,"PHASE2":2468,"PHASE3":2470,"PHASE4":2472,"NA":2474},{"trials":2465,"activeCount":71},[],{"trials":2467,"activeCount":71},[],{"trials":2469,"activeCount":71},[],{"trials":2471,"activeCount":71},[],{"trials":2473,"activeCount":71},[],{"trials":2475,"activeCount":71},[2476],{"nctId":2380,"briefTitle":2381,"status":188,"phases":2477,"primaryCompletion":2383,"completion":2383,"start":2384,"enrollment":2385,"conditions":2478,"interventions":2479},[64],[2387,24],[2389,2390,196,2391,2391,2391,2391,2391,2391],{"intervention":2481,"totalTrials":67,"cells":2482},"Olanzapine or amisulpride",{"EARLY_PHASE1":2483,"PHASE1":2485,"PHASE2":2487,"PHASE3":2489,"PHASE4":2491,"NA":2493},{"trials":2484,"activeCount":71},[],{"trials":2486,"activeCount":71},[],{"trials":2488,"activeCount":71},[],{"trials":2490,"activeCount":71},[],{"trials":2492,"activeCount":71},[],{"trials":2494,"activeCount":71},[2495],{"nctId":2496,"briefTitle":2497,"status":188,"phases":2498,"primaryCompletion":2499,"completion":2500,"start":1241,"enrollment":886,"conditions":2501,"interventions":2504},"NCT01029769","Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia",[64],"2014-03","2015-03",[17,2502,2503],"Schizoaffective Disorder","Schizophreniform Disorder",[2481],{"intervention":2506,"totalTrials":67,"cells":2507},"Fluticasone",{"EARLY_PHASE1":2508,"PHASE1":2510,"PHASE2":2512,"PHASE3":2514,"PHASE4":2516,"NA":2518},{"trials":2509,"activeCount":71},[],{"trials":2511,"activeCount":71},[],{"trials":2513,"activeCount":71},[],{"trials":2515,"activeCount":71},[],{"trials":2517,"activeCount":71},[],{"trials":2519,"activeCount":71},[2520],{"nctId":2521,"briefTitle":2522,"status":202,"phases":2523,"primaryCompletion":2524,"start":1360,"enrollment":296,"conditions":2525,"interventions":2527},"NCT01624129","New Serological Markers for Eosinophilic Esophagitis",[],"2012-10",[2526],"Eosinophilic Esophagitis",[2506],{"intervention":2529,"totalTrials":67,"cells":2530},"Abemaciclib",{"EARLY_PHASE1":2531,"PHASE1":2533,"PHASE2":2535,"PHASE3":2537,"PHASE4":2539,"NA":2541},{"trials":2532,"activeCount":71},[],{"trials":2534,"activeCount":71},[],{"trials":2536,"activeCount":71},[],{"trials":2538,"activeCount":71},[],{"trials":2540,"activeCount":71},[],{"trials":2542,"activeCount":71},[2543],{"nctId":2544,"briefTitle":2545,"status":188,"phases":2546,"primaryCompletion":2547,"completion":2548,"start":2549,"enrollment":2550,"conditions":2551,"interventions":2553},"NCT04681768","Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients",[],"2025-01-20","2025-04-01","2020-12-22",95,[2552],"Breast Cancer\u002F Metastatic Breast Cancer",[2529],{"intervention":2424,"totalTrials":67,"cells":2555},{"EARLY_PHASE1":2556,"PHASE1":2558,"PHASE2":2560,"PHASE3":2562,"PHASE4":2564,"NA":2566},{"trials":2557,"activeCount":71},[],{"trials":2559,"activeCount":71},[],{"trials":2561,"activeCount":71},[],{"trials":2563,"activeCount":71},[],{"trials":2565,"activeCount":71},[],{"trials":2567,"activeCount":71},[2568],{"nctId":2417,"briefTitle":2418,"status":188,"phases":2569,"primaryCompletion":2420,"completion":1241,"start":332,"enrollment":224,"conditions":2570,"interventions":2571},[],[2422],[2393,2424,2425],{"intervention":2425,"totalTrials":67,"cells":2573},{"EARLY_PHASE1":2574,"PHASE1":2576,"PHASE2":2578,"PHASE3":2580,"PHASE4":2582,"NA":2584},{"trials":2575,"activeCount":71},[],{"trials":2577,"activeCount":71},[],{"trials":2579,"activeCount":71},[],{"trials":2581,"activeCount":71},[],{"trials":2583,"activeCount":71},[],{"trials":2585,"activeCount":71},[2586],{"nctId":2417,"briefTitle":2418,"status":188,"phases":2587,"primaryCompletion":2420,"completion":1241,"start":332,"enrollment":224,"conditions":2588,"interventions":2589},[],[2422],[2393,2424,2425],{"intervention":2591,"totalTrials":67,"cells":2592},"Hyaluronic Acid",{"EARLY_PHASE1":2593,"PHASE1":2595,"PHASE2":2597,"PHASE3":2599,"PHASE4":2601,"NA":2603},{"trials":2594,"activeCount":71},[],{"trials":2596,"activeCount":71},[],{"trials":2598,"activeCount":71},[],{"trials":2600,"activeCount":71},[],{"trials":2602,"activeCount":71},[],{"trials":2604,"activeCount":71},[2605],{"nctId":2606,"briefTitle":2607,"status":188,"phases":2608,"primaryCompletion":2609,"completion":2610,"start":1295,"enrollment":2611,"conditions":2612,"interventions":2614},"NCT01239810","Intra-articular Hyaluronic Acid in Mild to Moderate Knee Osteoarthritis",[],"2006-11","2008-12",34,[2613],"Osteoarthritis",[2591],{"intervention":2616,"totalTrials":67,"cells":2617},"Combined chemotherapy with trabectedin followed by irinotecan",{"EARLY_PHASE1":2618,"PHASE1":2620,"PHASE2":2622,"PHASE3":2624,"PHASE4":2626,"NA":2628},{"trials":2619,"activeCount":71},[],{"trials":2621,"activeCount":71},[],{"trials":2623,"activeCount":71},[],{"trials":2625,"activeCount":71},[],{"trials":2627,"activeCount":71},[],{"trials":2629,"activeCount":71},[2630],{"nctId":2631,"briefTitle":2632,"status":202,"phases":2633,"primaryCompletion":2634,"completion":2635,"start":2383,"enrollment":2028,"conditions":2636,"interventions":2640},"NCT02509234","Trabectedin and Irinotecan for Refractory Pediatric Sarcomas",[],"2016-07","2017-07",[2637,2638,2639],"Recurrent Childhood Soft Tissue Sarcoma","Recurrent Ewing Sarcoma","Recurrent Rhabdomyosarcoma",[2616]]